Overview

The Cannabinoid Safety and Regulation Act establishes a comprehensive federal regulatory framework for cannabis and cannabinoid products by amending the Federal Food, Drug, and Cosmetic Act. The bill's primary objectives are threefold: to bring cannabinoid products under rigorous federal safety and quality oversight comparable to other regulated consumer products, to address the public health risks associated with cannabis-impaired driving, and to prevent underage cannabis use. The legislation fills a significant regulatory gap created by the proliferation of hemp-derived cannabinoid products following the 2018 Farm Bill, which legalized hemp but left a patchwork of inconsistent state regulations governing cannabinoid products such as delta-8, delta-9, and delta-10 THC derivatives. By vesting primary regulatory authority in the FDA and coordinating with the Departments of Transportation, Agriculture, and Health and Human Services, the bill creates a unified federal approach to product safety, labeling, manufacturing standards, and market access for the rapidly growing cannabinoid product industry.

Key Points

• Amends the Federal Food, Drug, and Cosmetic Act to formally regulate cannabinoid products derived from hemp
• Establishes FDA as the primary regulatory authority over cannabinoid product safety, labeling, and manufacturing
• Creates a national framework to address cannabis-impaired driving through research, standards, and state grant programs
• Authorizes grant programs to prevent underage cannabis use
• Sets potency limits, serving size requirements, and packaging standards for cannabinoid products

Legal References

• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq.
• Agricultural Marketing Act of 1946
• Public Health Service Act

Core Provisions

The bill introduces a new chapter into the Federal Food, Drug, and Cosmetic Act governing cannabinoid products, with foundational definitions, registration requirements, product standards, labeling mandates, and enforcement tools. Under §201, the bill defines 'cannabinoid' to encompass chemical substances found in the Cannabis sativa L. plant, including delta-6a, delta-7, delta-8, delta-9, delta-10a, and delta-10 forms, as well as 'artificially or synthetically derived cannabinoids' produced through chemical synthesis, modification, or conversion. A 'cannabinoid product' is defined as any article containing or purporting to contain any quantity of one or more cannabinoids derived from hemp. Under §1103, all covered entities owning or operating facilities engaged in covered activities must register with the Secretary within 90 days of enactment, with new facilities required to register within 30 days of commencing operations. The Secretary is authorized to require certification of compliance with good manufacturing practice regulations and may promulgate such regulations within 9 months of enactment. Product standards under §1105 require the Secretary to adopt standards distinguishing between different product types, including edible and inhalable products, with periodic evaluation of those standards. Critically, §1104 imposes a hard potency cap of 5 milligrams of THC per serving and 50 milligrams per container for cannabinoid products intended for human consumption. Inhalable products delivered via electronic cannabinoid delivery systems are subject to a terpene content limit of 6 percent of total product weight for naturally occurring terpenes, with added terpenes prohibited. Labeling requirements under §1104 mandate disclosure of cannabinoid content, directions for use, and a statement that the FDA has not determined the product to be safe or effective for treating any condition. Products containing multiple servings must be readily divisible into single-serving portions, and liquid products may contain no more than one serving per container. The bill also addresses adulteration and misbranding under §1101, deeming products adulterated if they contain filthy, putrid, or decomposed substances or are contaminated by deleterious substances injurious to health, and misbranded if labeling violates regulations or if the product is falsely represented as a conventional food. The Secretary receives recall authority under §1106 for adulterated or misbranded products and may suspend facility registrations for regulatory violations. On the public safety side, §302 mandates a study evaluating and quantifying cannabis-impaired driving risks, §303 directs the Department of Transportation to develop prevention programs, §304 establishes a State Cannabis-Impaired Driving Prevention Grant Program, and §305 requires the Secretary to develop best practices for states and communities and, if feasible, establish a national impairment standard within 3 years of enactment with reassessment every 2 years thereafter. Section 202 authorizes grants to states to prevent underage cannabis use, with a minimum age of 21 established for all cannabinoid product sales.

Key Points

• Registration of covered entities within 90 days of enactment; new facilities within 30 days of commencing operations [§1103]
• THC potency cap: 5 mg per serving, 50 mg per container [§1104]
• Terpene content limit of 6% for inhalable products with naturally occurring terpenes [§1104]
• Mandatory FDA disclaimer on all cannabinoid product labels [§1104]
• Recall authority and facility registration suspension for violations [§1106]
• National cannabis impairment standard feasibility determination within 3 years, reassessed every 2 years [§305]
• Minimum purchase age of 21 for all cannabinoid products [§1102(jjj)]
• Good manufacturing practice regulations to be promulgated within 9 months of enactment [§1103]
• Remote sales regulations to be finalized within 3 years of enactment

Legal References

• Federal Food, Drug, and Cosmetic Act §201, 21 U.S.C. 321
• Federal Food, Drug, and Cosmetic Act §301
• Federal Food, Drug, and Cosmetic Act §402(f)
• Federal Food, Drug, and Cosmetic Act §403(r)(6)(C)
• Public Health Service Act §351
• Title 23, United States Code §409

Implementation

The FDA serves as the lead implementing agency, responsible for establishing and enforcing registration requirements, good manufacturing practice regulations, labeling standards, product standards, and recall and suspension authorities. The Secretary of Health and Human Services coordinates with the FDA on public health surveillance, data collection, and the development of best practices for cannabis-impaired driving prevention. The Department of Transportation and the National Highway Traffic Safety Administration are responsible for cannabis-impaired driving research, the development of prevention programs, and administration of the State Cannabis-Impaired Driving Prevention Grant Program. The Department of Agriculture and the Alcohol and Tobacco Tax and Trade Bureau play supporting roles in the regulatory framework. The Secretary of Health and Human Services and the Administrator of the Drug Enforcement Administration are required to enter into a memorandum of understanding to establish criteria for laboratory accreditation, ensuring that cannabinoid product testing is conducted in certified facilities. The bill establishes a registration fee structure capped at $500 for fiscal year 2026, with subsequent years adjusted by the Consumer Price Index for All Urban Consumers. Enforcement mechanisms include civil penalties of up to $15,000 per violation and up to $15,000,000 per proceeding for standard violations, with enhanced penalties of up to $25,000 per violation and $25,000,000 per proceeding for knowing violations. The Secretary may also impose no-cannabinoid-product-sale orders on repeat violators, with civil penalties attached. Covered entities are entitled to a hearing before imposition of such orders or suspension of facility registration. Reporting requirements include regular reports to Congress on implementation progress and corrective actions. The Secretary must maintain an up-to-date public list of registered facilities. The Federal share of state grant program costs is set at 80 percent, with states required to direct at least 10 percent of allocated funds toward specified prevention activities. The National Highway Traffic Safety Administration is tasked with evaluating whether the Standard Field Sobriety Test accurately identifies cannabis impairment as part of the national standard feasibility assessment.

Key Points

• FDA: primary regulatory authority for product safety, labeling, manufacturing, and enforcement
• DOT/NHTSA: cannabis-impaired driving research, prevention programs, and state grant administration
• USDA and TTB: supporting regulatory roles
• DEA-HHS memorandum of understanding for laboratory accreditation criteria
• Registration fees: $500 cap for FY2026, CPI-adjusted thereafter
• Civil penalties: up to $15M per proceeding; enhanced penalties up to $25M for knowing violations
• No-cannabinoid-product-sale orders available for repeat violators with hearing rights
• 80% federal cost share for state grant programs; 10% minimum for specified prevention activities
• Regular congressional reporting on implementation and corrective actions

Legal References

• Federal Food, Drug, and Cosmetic Act §553
• Title 5, United States Code
• Title 23, United States Code §402(c)(2)
• Section 104(a) of the Federally Recognized Indian Tribe List Act of 1994

Impact

The bill's most direct beneficiaries are consumers of cannabinoid products, who gain federal assurances of product safety, accurate labeling, and consistent potency standards that currently do not exist at the federal level. The regulatory framework eliminates the market for unregulated, potentially dangerous synthetic or adulterated cannabinoid products by requiring laboratory testing, good manufacturing practice compliance, and mandatory disclosure of cannabinoid content. States benefit from substantial federal grant funding for both cannabis-impaired driving prevention and underage use prevention programs. The bill authorizes $100,000,000 annually for fiscal years 2026 through 2030 for underage use prevention grants under §202, $40,000,000 annually for cannabis-impaired driving research and prevention under §303, $30,000,000 annually for related public health activities under §§302 and 303, and $25,000,000 annually for the State Cannabis-Impaired Driving Prevention Grant Program under Title 23. The administrative burden on the cannabinoid product industry is substantial. Manufacturers, distributors, importers, and retailers must register with the FDA, comply with good manufacturing practice regulations, meet labeling and packaging requirements, submit to laboratory testing, and adhere to potency and serving size limits. The 5 mg THC per serving cap will require reformulation of many existing products currently sold at higher potencies. Small businesses in the cannabinoid product space face disproportionate compliance costs relative to larger manufacturers. The bill's prohibition on sales to individuals under 21 and its serving size and packaging requirements are expected to reduce youth access and accidental overconsumption. The national impairment standard initiative, if successfully established, would provide law enforcement with a scientifically validated tool for identifying cannabis-impaired drivers, addressing a significant gap in current traffic safety enforcement.

Key Points

• Annual funding authorizations: $100M (underage use prevention), $40M (impaired driving prevention), $30M (public health activities), $25M (state grant program) for FY2026–2030
• Mandatory product reformulation for cannabinoid products exceeding 5 mg THC per serving
• Significant compliance costs for manufacturers, distributors, importers, and retailers
• Enhanced consumer protections through mandatory testing, labeling, and manufacturing standards
• Potential market consolidation as smaller operators face higher compliance burdens
• Improved traffic safety enforcement tools through national impairment standard development

Legal References

• Cannabinoid Safety and Regulation Act §202
• Cannabinoid Safety and Regulation Act §302
• Cannabinoid Safety and Regulation Act §303
• Cannabinoid Safety and Regulation Act §304
• Title 23, United States Code §409

Legal Framework

The bill operates primarily through amendments to the Federal Food, Drug, and Cosmetic Act, grounding its authority in Congress's power to regulate interstate commerce under Article I, Section 8 of the Constitution. The regulatory framework for cannabinoid products is built on the existing statutory architecture of the FDCA, extending the Secretary's existing authorities over food, drugs, and dietary supplements to a new category of regulated products. The bill's definition of cannabinoid products as articles derived from hemp connects to the Agricultural Marketing Act of 1946 and the 2018 Farm Bill's legalization of hemp, establishing a clear statutory lineage for federal jurisdiction. The bill does not explicitly preempt state law, but the establishment of federal registration, labeling, manufacturing, and potency standards creates a comprehensive federal floor that will interact with existing state cannabinoid product regulations. States that have enacted their own cannabinoid product regulations may face conflict preemption challenges where state standards are inconsistent with federal requirements, particularly regarding potency limits and labeling mandates. The grant programs under §§202, 304, and 409 of Title 23 operate through conditional spending, preserving formal state autonomy while creating strong financial incentives for state compliance with federal program requirements. The bill incorporates standard FDCA procedural protections, including hearing rights before imposition of no-cannabinoid-product-sale orders and facility registration suspensions, consistent with due process requirements under the Fifth Amendment. The recall authority under §1106 follows the model established for food and drug recalls under existing FDCA provisions. The feasibility determination for a national cannabis impairment standard under §305 is structured as a discretionary agency action subject to notice-and-comment rulemaking under the Administrative Procedure Act, with judicial review available under Title 5 of the United States Code. Laboratory accreditation criteria established through the DEA-HHS memorandum of understanding will carry regulatory weight in determining which testing results are acceptable for compliance purposes.

Legal References

• U.S. Constitution, Article I, Section 8 (Commerce Clause)
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq.
• Agricultural Marketing Act of 1946
• Administrative Procedure Act, 5 U.S.C. 551 et seq.
• Title 5, United States Code §552
• Title 23, United States Code
• Public Health Service Act §351
• Federally Recognized Indian Tribe List Act of 1994 §104(a)

Critical Issues

The bill faces several significant implementation and legal challenges. The 5 mg THC per serving potency cap is the most commercially disruptive provision, as it would require reformulation of a large portion of the existing cannabinoid product market and may drive consumers toward unregulated or illicit products that offer higher potencies. Industry opposition to this cap is expected to be intense, and litigation challenging the cap as arbitrary under the Administrative Procedure Act is foreseeable. The definition of 'artificially or synthetically derived cannabinoid' is broad and may create classification ambiguities for products produced through common hemp extraction and refinement processes, generating compliance uncertainty and potential enforcement disputes. The 90-day registration deadline is aggressive given the size and fragmentation of the cannabinoid product industry, and the FDA will face substantial administrative capacity challenges in processing registrations, conducting inspections, and enforcing compliance across thousands of facilities simultaneously. The national cannabis impairment standard initiative faces fundamental scientific challenges, as there is no established consensus on a blood THC concentration that reliably correlates with driving impairment in the way that 0.08% BAC correlates with alcohol impairment. The bill's 3-year feasibility determination timeline may prove insufficient given the complexity of the underlying science, and a determination that a national standard is not feasible could undermine the bill's traffic safety objectives. The interaction between the federal regulatory framework and existing state cannabis regulatory programs—particularly in states with comprehensive adult-use cannabis markets—creates potential conflicts and jurisdictional tensions that the bill does not fully resolve. The bill's application to Indian Tribes, referenced in connection with grant programs, raises tribal sovereignty questions regarding the extent to which federal cannabinoid product regulations apply to tribally operated businesses. Finally, the substantial funding authorizations totaling over $850,000,000 across the five-year appropriations window will face scrutiny in the appropriations process, and the absence of guaranteed funding creates implementation risk for the grant programs that states are expected to rely upon.

Key Points

• 5 mg THC potency cap likely to face industry litigation as arbitrary and capricious under the APA
• Ambiguous definition of 'artificially or synthetically derived cannabinoid' creates classification and compliance uncertainty
• 90-day registration deadline is operationally aggressive for FDA and industry
• No scientific consensus on a reliable cannabis impairment threshold analogous to alcohol BAC standards
• Unresolved conflicts between federal framework and existing state adult-use cannabis regulatory programs
• Tribal sovereignty questions regarding applicability of federal regulations to tribally operated cannabinoid businesses
• Over $850M in five-year funding authorizations subject to appropriations uncertainty
• Risk of driving consumers to illicit markets if regulated products face strict potency and formulation restrictions

Legal References

• Administrative Procedure Act, 5 U.S.C. 706 (arbitrary and capricious review standard)
• Federal Food, Drug, and Cosmetic Act §402
• U.S. Constitution, Fifth Amendment (due process)
• Federally Recognized Indian Tribe List Act of 1994 §104(a)